MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
DURECT Corporation Book Value 2011-2026 | DRRX
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.2 M | 60.1 M | 92 M | 75.6 M | 22.9 M | 20 M | 21.5 M | 8.34 M | 14.9 M | 18.5 M | 30.7 M | 36.3 M | 3.48 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 92 M | 3.48 M | 34.6 M |
Quarterly Book Value DURECT Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.5 M | 14.4 M | 24.1 M | 29.9 M | 36.2 M | 54.7 M | 48.7 M | 58.3 M | 60.1 M | 68.5 M | - | 80.5 M | 92 M | 98 M | 106 M | 116 M | 75.6 M | 75.6 M | 75.6 M | 75.6 M | 86 M | 86 M | 86 M | 86 M | 50 M | 50 M | 50 M | 50 M | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 46.8 M | 46.8 M | 46.8 M | 46.8 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 116 M | 12.5 M | 55.5 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M |  USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.2 | 0.42 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
1.71 B | $ 2.69 | -0.56 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
649 M | $ 12.84 | 2.8 % | $ 657 M | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | $ 21.5 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
5.52 M | $ 6.03 | -10.27 % | $ 374 M | USA |
 |
Harrow Health
HROW
|
70.4 M | $ 54.06 | 8.3 % | $ 1.76 B | USA |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 1.23 | 1.65 % | $ 21.5 M |  China |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.7 | -1.74 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
-82 M | $ 7.51 | 4.16 % | $ 2.74 B | Canada |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.95 | -0.77 % | $ 55.5 M | USA |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 4.36 | -5.93 % | $ 574 M | USA |
 |
Sundial Growers
SNDL
|
1.13 B | $ 1.72 | -1.41 % | $ 3.37 M | Canada |
 |
Pacira BioSciences
PCRX
|
778 M | $ 25.21 | 3.07 % | $ 1.17 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 3.73 | 2.46 % | $ 4.63 M | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 4.28 | -1.41 % | $ 86.3 M | Canada |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 0.98 | 13.92 % | $ 22.9 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
4.32 B | $ 14.36 | 3.42 % | $ 1.97 B | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
32.3 M | $ 2.28 | 0.58 % | $ 308 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 1.11 | -4.31 % | $ 4.79 M | USA |
 |
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.11 | -6.06 % | $ 124 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
138 M | $ 9.62 | 5.25 % | $ 683 M | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
137 M | $ 5.33 | -2.14 % | $ 218 M | USA |
 |
SCYNEXIS
SCYX
|
73 M | $ 0.64 | -0.03 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
3.33 B | $ 9.43 | -3.03 % | $ 5.83 B | Canada |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 1.79 | 8.78 % | $ 18.7 M | USA |
 |
Zomedica Corp.
ZOM
|
240 M | - | -0.21 % | $ 98 M | USA |